Analysts and Calls -- C.E. Unterberg, Towbin

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Analysts and Calls -- C.E. Unterberg, Towbin

An SI Board Since December 2002

Posts	SubjectMarks	Bans
8	0	0

Emcee: Icebrg	Type: Unmoderated

Introduction Compact

Ken Trbovich CFA
Vice President
Life Sciences
Ken has six years experience writing equity research reports on public U.S. companies. Ken was previously Associate Director of Research for the Red Chip Review, a nationally recognized financial publication providing primary research to retail and institutional investors. While Ken was a generalist for four years, publishing research across a broad spectrum of industries, he has been focused on the specialty pharmaceutical market for the past two years. Ken has a BS in accounting from the University of Arizona and a Master of International Management from Thunderbird, and he is also a CFA charterholder.

David Bouchey PhD,
Vice President
Life Sciences
David brings 16 years of research experience to our team. He trained as a cell biologist, with experience in the fields of virology, cardiovascular biology, developmental biology, protein biochemistry, cell biology and immunology. David received a Ph.D. in Cell biology from the University of Virginia. He simultaneously earned an MS in Virology and an MBA in monetary economics from the University of Kentucky, where he was awarded the Carpenter Fellowship in Business.

Bryan Quinn
Associate Analyst
Life Sciences
Bryan Quinn joined C.E. Unterberg, Towbin Life Sciences Research as an Associate Analyst in August 2000. Prior to joining C.E. Unterberg, Towbin, Mr. Quinn conducted research in the area of cardiovascular biology at the University of Colorado Health Sciences Center. Mr. Quinn received B.S.degrees in Biology and Anthropology/Zoology from the University of Michigan.

Fred Green
Vice President
Fred Green joined C.E. Unterberg, Towbin in 2000 with over seven years of Investment Banking experience. Prior to C.E. Unterberg, Towbin, Mr. Green was with Bigelow & Company and focused on both public offerings and private placements, as well as strategic advisement for biotechnology companies. Prior to Bigelow & Company, Mr. Green was with EVEREN Securities from 1995 to 1997.

Fred Green received his B.S. in Finance from the University of Wyoming

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
8	>>Eric, I thought that this thread was about what Unterberg covers <g&g	Icebrg	-	12/21/2002
7	Eric, I thought that this thread was about what Unterberg covers <g>.	Sergio H	-	12/21/2002
6	No, sorry. I don't follow CLGY. Erik	Icebrg	-	12/20/2002
5	Ice, Unt should change their rating on CLGY. Any idea what's up? TIA.	Sergio H	-	12/20/2002
4	Northwest Biotherapeutics Nov , 18 , 2002 , 00:00 : Effective immediately, C.E	Icebrg	-	12/1/2002
3	ICOS Corporation November , 25 , 2002 , 00:00 : We are raising our 12-month pr	Icebrg	-	12/1/2002
2	Companies covered: <b>Bouchey</b> Abgenix, Inc.1 ABGX M. Perform/	Icebrg	-	12/1/2002
1	Ratings Criteria • Short-Term Buy: Over three to six months, 20% appreciation p	Icebrg	-	12/1/2002

Go to reply# or date (mm/dd/yy):